Mohammad Yaghoobi

Division of Gastroenterology

Mohammad Yaghoobi

MD, MSc (Epi), AFS, FRCPC

Assistant Professor, Division of Gastroenterology, Department of Medicine

Attending Gastroenterologist: Hamilton Health Sciences and St. Joseph's Hospital

 

 

 

 

Education and Professional Standing

Dr Yaghoobi is a gastroenterologist and an advanced endoscopist. He is an assistant professor of medicine and attending gastroenterologist at McMaster University and Hamilton Health Sciences. He received his medical degree from Tehran University School of Medicine followed by an AFS degree from University of Paris in France. He then completed simultaneous Master’s Degree in Health Research Methodology as well as a research and clinical fellowship at McMaster University. Afterward, he finished his residency in internal medicine at University of Toronto and his clinical fellowship in Gastroenterology and Hepatology at McGill University. He was then appointed as the Clinical Instructor in Advanced Endoscopy Program and staff gastroenterologist at the Medical University of South Carolina before accepting his current position at McMaster University.

Dr Yaghoobi is certified in both Internal Medicine and Gastroenterology and Hepatology from both the Royal College of Physicians and Surgeons of Canada and the American Board of Internal Medicine. He is fully licensed to practice medicine and gastroenterology and hepatology by the College of Physicians and Surgeons of Ontario.

Clinical and Research Interests

His clinical and academic interests include anemia, family history of digestive cancer or polyps, GI bleeding, Barrett’s esophagus, advanced endoscopic procedures, complex polyp removal, endoscopic ultrasound, ERCP and minimally invasive endoscopic surgeries. He is also expert in performing conventional meta-analysis, meta-analysis of diagnostic test accuracy as well as Health Technology Assessment.
Dr Yaghoobi sees and council the following patients in his subspecialty clinics only by referral:

  1. Familial digestive cancer
    1. Who is eligible? Any individual with one or more first- or second-degree relative with colon cancer or polyp, rectal cancer or polyp, esophageal cancer and stomach cancer.

    2. Most digestive cancers and precancerous polyps could be treated by endoscopic procedures without surgery and cured if caught in early stages. Family history is an important risk factor in developing digestive cancers. Individuals whose first- or second-degree relatives have been diagnosed with esophageal cancer, stomach cancer and colon or rectal cancer or polyps may be at increased risk of development of cancer and may require further screening as compared to those without family history. The risk is higher if the age of the involved relative is less than 60. Each individual will receive counseling regarding the risk of cancer and appropriate means to screen for those cancers. The most appropriate test, based on current recommendations, will be arranged if interested.
  2. Anemia
    1. Who is eligible? Patients with low blood count for any reason.

    2. The most common causes of anemia are blood loss from the digestive tract, dietary factors, inability to absorb iron or vitamins and systemic diseases that may end in low red blood cell count. Each patient undergoes comprehensive assessment for digestive causes of anemia and appropriate management will be provided based on the findings.   
  3. GI bleeding
    1. Who is eligible? Any person with bleeding from the upper or the lower digestive tract including blood in the stool, black stool or vomiting blood.

    2. Bleeding from the digestive tract could be due to different benign and malignant reasons. Further investigation is crucial to detect the source, to prevent major blood loss and to manage underlying cause. Any bleeding should be discussed with the family physician to identify the urgency of matter and the need for further investigations.
  4. Pancreatic cyst
    1. Who is eligible? Any individual with a known or newly diagnosed pancreatic cyst.

    2. Pancreatic cysts could be benign, precancerous or cancerous. Some cysts may not require further follow up and some might need frequent follow-up or even removal based on the type and the risk of cancer. Each patient with a pancreatic cyst should be seen by a specialist with expertise in this area. At McMaster Pancreatic Cyst Clinic each patient will undergo necessary investigations and further follow-ups and management will be arranged.

Publications and Editorial Positions

Dr Yaghoobi has published more than 70 peer-reviewed articles, editorials, invited reviews, abstracts, and book chapter, mainly as the lead author. His publications have been cited more than 1150 times. He was appointed as the first Editor-in-Chief of the ACG Case Reports Journal by the American College of Gastroenterology and is currently serving as member of Publication Committee and International Relation Committee at the American College of Gastroenterology. He has served as the referee for several international peer-reviewed journals. He also serves as the Editor-in-Chief of GI Perspective by the Canadian Digestive Health Foundation (CDHF), an editor of the Cochrane Upper Gastrointestinal and Pancreatic Diseases Review Group and a member of editorial board of the Canadian Journal of Gastroenterology and Hepatology.

Selected Publications

  1. Davidson TB, Yaghoobi M, Davidson BR, Gurusamy KS. Amylase in drain fluid for the diagnosis of pancreatic leak in post-pancreatic resection. Cochrane Database Syst Rev. 2017 Apr 7;4:CD012009.
  2. Yaghoobi M, McNabb-Baltar J, Bijarchi R, Hunt RH. What is the quantitative risk of gastric cancer in the first-degree relatives of patients? A meta-analysis. World J Gastroenterol 2017 April 7; 23(13): 2435-2442.
  3. Hunt RH, Yaghoobi M. The Esophageal and Gastric Microbiome in Health and Disease. Gastroenterol Clin North Am. 2017 Mar;46(1):121-141.
  4. Tamburrino D, Riviere D, Yaghoobi M, Davidson BR, Gurusamy KS. Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev. 2016 Sep 15;9:CD011515.
  5. Yaghoobi M, McNabb-Baltar J, Bijarchi R, Cotton PB. Pancreatic Enzyme Supplements Are Not Effective for Relieving Abdominal Pain in Patients with Chronic Pancreatitis: Meta-Analysis and Systematic Review of Randomized Controlled Trials. Can J Gastroenterol Hepatol. 2016;2016:8541839.
  6. Yaghoobi M. Bone marrow-derived stem cells in pathogenesis of Helicobacter pylori-associated gastric cancer. Clinical and Translational Gastroenterology (2015) 6, e110; doi:10.1038/ctg.2015.35.
  7. Cotton PB and Yaghoobi M (2015). Adverse events; definitions, avoidance and management. In Peter B Cotton and Joseph Leung. ERCP: The Fundamentals (Edition 2). Oxford, England. John Wiley & Sons, Ltd. ISBN: 978-1-118-76941-6
  8. Yaghoobi M, Pauls Q, Durkalski V, Romagnuolo J, Fogel EL, Tarnasky PR, Aliperti G, Freeman ML, Kozarek RA, Jamidar PA, Wilcox CM, Elta GH, Hawes RH, Wood-Williams A, Cotton PB. Incidence and predictors of post-ERCP pancreatitis in patients with suspected sphincter of Oddi dysfunction undergoing biliary or dual sphincterotomy. Results from the EPISOD prospective multi-center randomized sham-controlled study. Endoscopy. 2015 Oct;47(10):884-890.
  9. Yaghoobi M, Romagnuolo J. Sphincter of Oddi Dysfunction: Updates from the Recent Literature. Curr Gastroenterol Rep. 2015 Aug;17(8):455.
  10. Yaghoobi M. ERCP for Gallstone Pancreatitis. N Engl J Med. 2014 May 15;370(20):1955.
  11. Yaghoobi M. Treatment of patients with new diagnosis of achalasia: laparoscopic Heller's myotomy may be more effective than pneumatic dilation. Gastrointest Endosc. 2014 Aug;80(2):360.
  12. Kopylov U, Al-Taweel T, Yaghoobi M, Nauche B, Bitton A, Lakatos PL, Ben-Horin S, Afif W, Seidman EG. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis. J Crohns Colitis. 2014 Jul 24. pii: S1873-9946(14)00216-5.
  13. Yaghoobi M, Rolland S, McNabb-Baltar J, Bijarchi R, Waschke K, Szego P. Rectal indomethacin in preventing post-ERCP pancreatitis: a first metaanalysis of randomized controlled trials. Aliment Pharmacol Ther. 2013;38(9):995-1001.
  14. Yaghoobi M, Mayrand S, Martel M, Roshan Afshar I, Bijarchi R, Barkun AN. Pneumatic Dilation Versus Laparoscopic Heller Myotomy in Treatment of Achalasia: A Meta-Analysis of Randomized Controlled Trials. Gastrointestinal Endoscopy 2013;78(3):468-75.
  15. Yaghoobi M, Le Gouvello S, Aloulou N, Duprez-Dutreuil C, Walker F, Sobhani I. FoxP3 overexpression and CD1a(+) and CD3(+) depletion in anal tissue as possible mechanisms for increased risk of human papillomavirus-related anal carcinoma in HIV infection. Colorectal Dis. 2011;13(7):768-73.
  16. Yaghoobi M, Yuan Y, Hunt RH.Is eradication of H. pylori infection ever followed by GERD? A meta-analysis. Am J Gastroenterol. 2010 May;105(5):1007-13.
  17. Yaghoobi M, Padol S, Yuan Y, Hunt RH.Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis. Eur J Gastroenterol Hepatol 2010 May;22(5):583-90.
  18. Yaghoobi M, Bijarchi R, Narod S. Family history and the risk of gastric cancer. Br J Cancer. 2010 Jan;102(2):237-4.
  19. Hunt RH, Armstrong D, Yaghoobi M, James C. Pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg versus esomeprazole 40 mg in healthy male subjects. Aliment Pharmacol Ther. 2008 Jul;28(2):187-99.
  20. Yaghoobi M, Koren G, Nulman I. Challenges to diagnosing colorectal cancer during pregnancy. Can Fam Physician. 2009 Sep;55(9):881-5.
  21. Hunt RH, Armstrong D, Yaghoobi M, James C, Chen Y, Leonard J, Shin JM, Lee E, Tang-Liu D, Sachs G. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008 Jul;28(2):187-99.
  22. Hunt RH, Yuan Y, Yaghoobi M. GERD: New Strategies and New Failures. Journal of Clinical Gastroenterology 2007;41(S2): 72-80.
  23. Mikaeli J, Yaghoobi M, Montazeri G, Ansari R, Malekzadeh R. Efficacy of botulinum toxin injection before pneumatic dilatation in the patients with idiopathic achalasia. Dis Esophagus. 2004;17(3):213-7.
  24. Yaghoobi M, Rakhshani N, Sadr F, Bijarchi R, Joshaghani Y, Mohammadkhani A, Attari A, Akbari MR, Hormazdi M, Malekzadeh R. Hereditary risk factors for the development of gastric cancer in younger patients. BMC Gastroenterol. 2004 Oct 27;4(1):28.
  25. Yaghoobi M, Mikaeli J, Montazeri G, Nouri N, Sohrabi MR, Malekzadeh R. Correlation between Clinical Severity Score and the Lower Esophageal Sphincter Relaxation Pressure in Idiopathic Achalasia. Am J Gastroenterol. 2003 Feb;98(2):278-83.